A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Chinese Subjects With Higher-Risk Myelodysplastic Syndromes
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 01 Mar 2018 Planned End Date changed from 1 Feb 2018 to 28 Mar 2018.
- 30 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
- 04 May 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017.